Floatz logo

Lenalidomide

T-Cell/Histiocyte Rich Large B Cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

31 Active assets in the T-Cell/Histiocyte Rich Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Vincristine Sulfate
Northwestern University
Phase 2/3BB
Prednisone
Ruijin Hospital
Phase 2/3BB
Adriamycin
Ruijin Hospital
Phase 2/3BB
Cyclophosphamide
Ruijin Hospital
Phase 2/3BB
Rituximab
Ruijin Hospital
Phase 2/3BB

View all 32 →

Same molecule, other indications

Lenalidomide is also rated in:

adult T-cell leukemia/lymphomaActive
BBB
Indicative · Phase 2
74 / 100
View asset →
plasma cell neoplasmActive
BBB
Indicative · Phase 3
72 / 100
View asset →
B-cell non-Hodgkin lymphomaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →